CORRADO, Francesco
 Distribuzione geografica
Continente #
EU - Europa 5.315
NA - Nord America 5.240
AS - Asia 2.828
SA - Sud America 1.036
AF - Africa 81
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.511
Nazione #
US - Stati Uniti d'America 5.119
RU - Federazione Russa 1.735
SG - Singapore 1.264
BR - Brasile 909
IE - Irlanda 879
CN - Cina 859
SE - Svezia 822
DE - Germania 388
IT - Italia 343
HK - Hong Kong 322
UA - Ucraina 287
PL - Polonia 206
FI - Finlandia 181
GB - Regno Unito 165
FR - Francia 153
VN - Vietnam 137
IN - India 67
CA - Canada 57
AR - Argentina 47
BE - Belgio 46
MX - Messico 42
ZA - Sudafrica 27
BD - Bangladesh 24
NL - Olanda 24
EC - Ecuador 23
JP - Giappone 23
ES - Italia 20
MA - Marocco 20
TR - Turchia 20
IQ - Iraq 18
AT - Austria 14
VE - Venezuela 14
CZ - Repubblica Ceca 13
UZ - Uzbekistan 12
ID - Indonesia 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 8
PE - Perù 8
AL - Albania 7
CO - Colombia 7
IR - Iran 7
PK - Pakistan 7
AU - Australia 6
CI - Costa d'Avorio 6
EG - Egitto 6
KE - Kenya 6
KZ - Kazakistan 6
PY - Paraguay 6
DO - Repubblica Dominicana 5
GY - Guiana 5
JM - Giamaica 5
RO - Romania 5
SA - Arabia Saudita 5
BO - Bolivia 4
JO - Giordania 4
LT - Lituania 4
LU - Lussemburgo 4
NP - Nepal 4
TN - Tunisia 4
HN - Honduras 3
IL - Israele 3
KH - Cambogia 3
KR - Corea 3
LV - Lettonia 3
SN - Senegal 3
BB - Barbados 2
BY - Bielorussia 2
CG - Congo 2
CH - Svizzera 2
CL - Cile 2
CR - Costa Rica 2
DZ - Algeria 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
OM - Oman 1
PH - Filippine 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 14.508
Città #
Dublin 878
Moscow 831
Ashburn 713
Singapore 690
Chandler 643
Jacksonville 574
Dallas 525
Nyköping 431
Beijing 376
Hong Kong 322
Warsaw 189
Boardman 160
Ann Arbor 157
Los Angeles 145
Princeton 129
Cambridge 127
Messina 120
Munich 111
Medford 110
Dearborn 106
The Dalles 106
Des Moines 99
São Paulo 77
Buffalo 62
Woodbridge 61
Ho Chi Minh City 52
New York 49
Brussels 46
Shenyang 40
Jinan 39
Turku 37
Catania 36
Wilmington 36
Bremen 35
Tianjin 32
Hyderabad 28
Frankfurt am Main 27
Düsseldorf 26
Belo Horizonte 25
Hebei 25
Lancaster 25
Nanjing 25
Redondo Beach 24
Zhengzhou 24
Helsinki 23
Houston 23
Montreal 23
Hanoi 22
Lauterbourg 22
London 21
San Mateo 21
Tokyo 21
Brooklyn 20
Rio de Janeiro 20
Santa Clara 20
Seattle 20
Washington 20
Denver 18
Stockholm 18
Porto Alegre 17
Curitiba 16
Johannesburg 16
Ningbo 15
Orem 15
Amsterdam 14
Boston 14
Chennai 14
Haikou 14
Hangzhou 14
Brasília 13
Sorocaba 13
Atlanta 12
Auburn Hills 12
Dong Ket 12
Guangzhou 12
Ottawa 12
Taizhou 12
Mexico City 10
Pune 10
San Francisco 10
Baghdad 9
Campinas 9
Manchester 9
Nanchang 9
Poplar 9
Quito 9
Salvador 9
Tashkent 9
Toronto 9
Wroclaw 9
Augusta 8
Baku 8
Changsha 8
Columbus 8
Guarulhos 8
Guayaquil 8
Jakarta 8
Milan 8
Uberlândia 8
Viagrande 8
Totale 9.132
Nome #
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial 189
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 185
Metabolic effects of breastfeeding in women with previous gestational diabetes diagnosed according to the IADPSG criteria 179
Adiponectin and insulin resistance in early- and late-onset pre-eclampsia 173
Italian risk factor-based screening for gestational diabetes. 165
ADAM 12 and PAPP-A at 14–17 weeks' gestation as biomarkers of pre-eclampsia. 163
Abnormal glucose tolerance later in life in women affected by glucose intolerance during pregnancy 159
Association between maternal serum high mobility group box 1 levels and pregnancy complicated by gestational diabetes mellitus 159
A 45,MALE WITH MOLECULAR EVIDENCE OF A TRANSLOCATION OF Y EUCHROMATIN ONTO CHROMOSOME 1 157
Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial 155
Effects of myo-inositol on glucose variability in women with gestational diabetes 153
A single abnormal value of the glucose tolerance test is related to increased adverse perinatal outcome. 152
Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs 152
Myo-inositol may prevent gestational diabetes in PCOS women 149
A 45,X MALE WITH MOLECULAR EVIDENCE OF A TRANSLOCATION OF Y- EUCHROMATIN ONTO CHROMOSOME-1 147
Association of Gestational Weight Gain With Maternal and Infant Outcomes: A Systematic Review and Meta-analysis 146
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. 145
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. 145
Perinatal outcome in a Caucasian population with gestational diabetes and preexisting diabetes first diagnosed in pregnancy 144
Abortività spontanea ed età materna avanzata. 142
Cardiac diastolic evaluation in pregnant women with abnormal glucose tolerance: an opportunity to detect the early and subclinical alterations and prevent cardiovascular diseases 139
Intravaginal vs. intracervical PGE(2) gel first application for labor induction 137
Peroxisome proliferator-activated receptor modulation during metabolic diseases and cancers: master and minions 136
Wnt antagonist sclerostin and Dickkopf-1 in gestational diabetes 136
Cardiovascular effects of the phytoestrogen genistein 134
"Anticorpi antifosfolipidi ed aborto ricorrente". 134
Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: A two-year randomized, double-blind, placebo-controlled study 132
Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction 131
C-reactive protein as an early predictor of gestational diabetes mellitus 131
First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. 131
OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. 130
Glucose Tolerance and insulin secretion in pregnancy 129
Cardiovascular effects of raloxifene hydrochloride 129
Compliance with hormone replacement therapy in postmenopausal Sicilian women 128
Screening for gestational diabetes in Sicily. 127
Celiac disease in pregnancy: not always a relapse 126
Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study 126
Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study 125
Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. 125
GENISTEIN AGLYCONE DOES NOT AFFECT THYROID FUNCTION: RESULTS FROM A THREE-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 125
ICAM-1 in maternal serum and amniotic fluid as an early marker of preeclampsia and IUGR 123
Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo controlled study. 123
First trimester serum neutrophil gelatinase-associated lipocalin in gestational diabetes 123
PREGNANCY IN ESSENTIAL THROMBOCYTHEMIA DURING ASPIRIN TREATMENT 122
Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders 121
A randomised trial of progesterone prophylaxis after midtrimester amniocentesis 121
Maternal serum PAPP-A as an early marker of obstetric complications? 121
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study 120
Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes–a randomized and open-label, placebo-controlled clinical trial 120
EFFECTS OF THE PHYTOESTROGEN GENISTEIN ON CARDIOVASCULAR RISK FACTORS IN POSTMENOPAUSAL WOMEN. 120
Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin system in early postmenopausal women 119
Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women - A randomized trial 119
Midtrimester amniotic fluid adiponectin in normal pregnancy. 117
Diagnosis of gestational diabetes mellitus: italian perspectives on risk factor based screening 117
One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome 116
Positive association between a single abnormal glucose tolerance test value in pregnancy and subsequent abnormal glucose tolerance 115
Differences in body composition between post-menopausal women with and without dyslipidemia. 114
Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy 112
Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. 112
Improvement of selective screening strategy for gestational diabetes through a more accuratedefinition of high-risk groups 112
Modalità di prelievo in corso d'amniocentesi ed outcome ostetrico 111
Myo-inositol supplementation and the onset of gestational diabetes mellitus in pregnant women with a family hystory of type 2 diabetes. A prospective, randomized, placebo controlled study 111
Is mid-trimester maternal serum inhibin-A a marker of preeclampsia or intrauterine growth restriction? 110
Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study 110
Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and Placebo-controlled Study 110
First trimester serum PAPP-A and NGAL in the prediction of late-onset preeclampsia 110
Diagnosis of celiac disease in pregnancy and puerperium: think about it 109
SCLEROSTIN AND DICKKOPF-1 IN PREGNANT WOMEN WITH GESTATIONAL DIABETES 109
The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats 108
Role of urocortin in pregnancy: an update and future perspectives 108
La disfunzione diastolica nel diabete gestazionale 106
CORRESPONDENCE BETWEEN FIRST TRIMESTER FASTING GLICEMIA AND ORAL GLUCOSE TOLERANCE TEST IN GESTATIONAL DIABETES DIAGNOSIS 106
Midtrimester Amniotic Fluid Leptin and Insulin Levels and Subsequent Gestational Diabetes. 105
Myo-inositol in Down syndrome amniotic fluid. A case-control study. 104
Sindrome mano-piede-utero. Descrizione di un caso ad ereditarietà autosomica recessiva. 102
Effects of prepregnancy body mass index and weight gain during pregnancy on perinatal outcome in glucose-tolerant women. 102
Effects of a phyto complex on well-being of climacteric women 102
Prevalence of risk factors in the screening of carbohydrate intolerance in pregnancy 101
Screening for gestational diabetes in Sicily 101
VALUTAZIONE LONGITUDINALE DI DONNE CON RIDOTTA TOLLERANZA GLUCIDICA IN GRAVIDANZA 101
A 45,X male with molecular evidence of a translocation of Y euchromatin onto chromosome 1 100
Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study 100
Prevalenza dei fattori di rischio associati al diabete gestazionale e alla ridotta tolleranza glucidica in gravidanza 100
Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. 100
Effects of a New Flavonoid and Myo-Inositol Supplement on Some Biomarkers of Cardiovascular Risk in Postmenopausal Women: A Randomized Trial 100
Anti-SARS-CoV2 IgG are present in the amniotic fluid of both infected and vaccinated women at second trimester of pregnancy: a cohort study 99
Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women 99
Predittività dell’OGTT sugli outcomes clinici ed ostetrici nella ridotta tolleranza glucidica in gravidanza 99
Intolleranza glucidica e disordini ipertensivi in gravidanza. 99
TESTICULAR REGRESSION SYNDROME - A CASE-REPORT 98
Myo-Inositol for the Prevention of Gestational Diabetes Mellitus. A Brief Review 98
Spontaneous abortion and advanced maternal age 97
Pregnancy outcome following mid-trimester amniocentesis 95
I LIVELLI SIERICI DI NGAL NEL PRIMO TRIMESTRE DELLA GRAVIDANZA SONO PREDITTIVI DELL’INSORGENZA DI DIABETE GESTAZIONALE. 93
Prenatally identified Pallister-Killian syndrome: Ultrasound pattern and diagnostic considerations 93
How to achieve high-quality oocytes? The key role of myo-Inositol and melatonin 92
Myoinositol plus α‑lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study 92
Inflammatory markers in women with a recent history of gestational diabetes mellitus 91
VARIABILITA' GENOTIPICA E FENOTIPICA DELLA SINDROME DI PATAU.. OSSERVAZIONE DI UN CASO 91
Prostate-specific antigen in prenatal screening for Down's syndrome 90
Totale 12.189
Categoria #
all - tutte 51.521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.521


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021523 0 0 0 0 0 105 56 98 45 109 72 38
2021/2022979 11 155 18 28 35 11 60 37 24 239 105 256
2022/20232.621 181 260 140 171 218 263 15 155 1.094 15 82 27
2023/2024703 54 96 46 97 64 113 16 21 7 46 7 136
2024/20252.796 44 34 52 196 127 114 43 583 674 200 283 446
2025/20264.718 504 554 550 597 680 1.833 0 0 0 0 0 0
Totale 14.703